This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEC0L0PD_M.jpg
Cabozantinib has been a big money maker. For instance, the uptake of Cabometyx, a tablet formulation of cabozantinib, to treat patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy, has been very strong.
The drug’s label was also expanded to treat previously-untreated, advanced renal cell carcinoma. This has significantly boosted demand for the drug. In fact, kidney cancer is one of the most commonly diagnosed forms of cancer in both men and women, and renal cell carcinoma is the most common form of kidney cancer in adults.
